Ivosidenib plus azacitidine is also being investigated in a phase 1b/2 open‐label, randomized, multicenter trial in adults with newly diagnosed AML with an IDH1 mutation who are ineligible for intensive therapy.49 Here, IDH1 is linked to acute myeloid leukemia.